Kornimate/medical-research-clean huggingface dataset:
engagement with digital mental health (dmh) technologies in pediatric primary care

Conditions: Mental Health

Summary: the goal of this study is to use and adapt existing digital mental health technologies to advance the engagement, assessment, detection, treatment, and delivery of services for pediatric mental health. specifically, user-centered design methodologies and an implementation science framework will be used to guide the development and implementation of the teen assess, check, and heal (teach) system into a pediatric primary care clinic serving teens and families from underserved communities. study objectives include: 1. collaborating with underserved teens and their parents to identify strategies to target top barriers to engagement as well as top ethical concerns and requirements for cultural relevance, usability, and usefulness of the teach system (phase 1) 2. refining the plan for implementing the teach system through observations, interviews, and co-design workshops with pediatric primary care pediatricians and staff (phase 2), and 3. implementing the teach system into a primary care clinics and evaluating it in a randomized trial. (phase 3) the team will measure engagement outcomes and satisfaction with the teach system.


Eligibility criteria:
inclusion criteria: * are receiving care at specified rush university health system and university of illinois at chicago pediatric primary care locations * are between 13-17 years of age * are able to speak and read in english * symptoms of anxiety disorder exclusion criteria: * absence of the above inclusion criteria.

Keywords: digital mental health technology digital mental health mental health disorders mental health wellness
a study of brivaracetam in subjects with partial onset seizures

Conditions: Epilepsy, Focal

Summary: this trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy


Eligibility criteria:
inclusion criteria: * well-characterized focal epilepsy or epileptic syndrome according to the international league against epilepsy (ilae) classification * subjects with a history of partial onset seizures * subjects having at least 4 partial onset seizures during the baseline period and at least 2 partial onset seizures per month during the 3 months preceding visit 1 * subjects being uncontrolled while treated by 1 or 2 concomitant antiepileptic drug(s) aed(s) being stable * male/ female subjects from 16 to 65 years, both inclusive. subjects under 18 years may only be included where legally permitted and ethically accepted exclusion criteria: * seizure type ia non-motor as only seizure type * history or presence of seizures occurring only in clustered patterns * history of cerebrovascular accident (cva) * presence of any sign suggesting rapidly progressing brain disorder or brain tumor

Keywords: epilepsy focal epilepsy partial onset seizures brivaracetam
efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. a second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. a third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

this study assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. a second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. a third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

Eligibility criteria:
inclusion criteria: * subject has had stable moderate to severe plaque psoriasis for at least 6 months * subject has involved body surface area (bsa) ≥ 10%, pasi ≥ 12, and spga ≥ 3 at screening and at baseline exclusion criteria: * subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations * subject has known history of crohn's disease * subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol * subject has not stopped using certain psoriasis therapies as defined in the study protocol * subject has previously used ustekinumab or any anti-il-17 biologic therapy * subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study * female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile

Keywords: psoriasis, brodalumab, amg 827
corneal changes in estrogen-dependent breast cancer after hormonal treatment

Conditions: Braest Cancer; Dry Eye

Summary: aromatase inhibitors (ai) therapy is the treatment of choice for estrogen receptor-positive breast cancer (bc). while ais effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. this work evaluated the anterior segment changes in estrogen-dependent bc after hormonal treatment.

aromatase inhibitors (ai) therapy is an important treatment for estrogen receptor-positive breast cancer (bc). this work evaluated the eye anterior segment changes in estrogen-dependent bc after hormonal treatment. this cross-sectional study was conducted on female patients aged ≥18 who received treatment for bc. patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system

Eligibility criteria:
inclusion criteria: * females diagnosed with breast cancer exclusion criteria: * uncontrolled diabetes , auto immune diseases

Keywords: corneal changes breast cancer hormonal treatment
biomarkers in pulmonary hypertension associated to interstitial lung disease

Conditions: Interstitial Lung Disease; Pulmonary Hypertension; Biomarkers

Summary: the presence of an abnormally increased pulmonary blood pressure worsens the prognosis of patients with interstitial pulmonary disease. the aim of this study is to estimate the frequency of an increased blood pressure in the lungs among patient with interstitial pulmonary disease, and to evaluate the use of different biomarkers in diagnosis of the condition.

the presence of increased pulmonary blood pressure is established by echocardiography and confirmed by right heart catheterization. the ability of nt-probnp, vwf, troponin-t, d-dimer and exhaled no to predict the presence of increased pressure in the pulmonary circulation is evaluated.

Eligibility criteria:
inclusion criteria: * interstitial pulmonary disease

Keywords: interstitial lung disease pulmonary hypertension biomarkers nt-pro-bnp von willebrand factor d-dimer exhaled no troponin-t
education and counseling for abstinence from tobacco after pregnancy

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: the purpose of this study is to develop and field test a maintenance of smoking abstinence program designed for a predominately low-income, high-risk population of women from a wide variety of ethnic and racial backgrounds who have quit smoking because of (or during) their pregnancy.

background: pregnancy is an ideal time to help underserved young women to stop smoking cigarettes and remain abstinent for life. the field has made great progress in assisting women to quit during this time. unfortunately, maintenance of this highly significant behavior change is dismal. up to 75% of those who quit for pregnancy end up returning to smoking after delivery of the newborn. for underserved women, pregnancy is one of the few times that they have an extended contact with the health care system. therefore, there is an opportunity to help these women quit smoking for the health of their fetus in addition to their own health. to date, there has been insufficient research on how best to maintain abstinence during the critical postpartum period, during which a unique constellation of risk factors (including sleep deprivation, variations in negative mood, and increased stress) heighten the probability of relapse. the potential payoff is enormous. the literature, while not extensive, provides sufficient guidance and justification for the specific approach and intervention components the study has chosen. design narrative: this study will develop and field test a maintenance of smoking abstinence program to be designed for a predominately low-income, high-risk population of women from a wide variety of ethnic and racial backgrounds who have quit smoking because of (or during) their pregnancy. the study will compare biologically confirmed postpartum smoking relapse rates of women who receive an educational intervention during pregnancy combined with sustained telephone counseling after that intervention, with women who receive only an educational intervention. participants will begin at 28 weeks prenatal and will be followed through 1, 3, 6, and 12 months postpartum. the specific aims of the current maintenance study are: 1) to compare biochemically confirmed smoking abstinence rates of women who quit smoking during their pregnancy and who receive an intervention based on telephone counseling using motivational interviewing versus quitters who receive usual care, maintenance of abstinence will be assessed at 1, 3, 6, and 12 months postpartum; and 2) to collect both qualitative and quantitative data to better understand short term and long term maintenance mediators and moderators of abstinence postpartum for women of low socioeconomic status (ses) who quit smoking during pregnancy.

Eligibility criteria:
inclusion criteria: * smoked tobacco immediately before pregnancy exclusion criteria: * smoked tobacco in the previous 7 days when contacted at 28 weeks gestation * no telephone access
levoﬂoxacin and bismuth-containing therapy versus quadruple therapy as second-line treatment of resistant helicobacter pylori infection

Conditions: Cure Rate of Helicobacter Pylori Infection

Summary: to test the efﬁcacy of 14 day levoﬂoxacin and bismuth-containing second-line therapy for resistant helicobacter pylori infection, to compare with the classical quadruple therapy.


Eligibility criteria:
inclusion criteria: * all patients had failed h.pylori therapies including clarithromycin, metronidazole and/or amoxicillin (if not allergic) before. exclusion criteria: * patients less than 18 years old, * previous gastric surgery, * pregnancy, * lactation, * major systemic diseases, * administration of antibiotics, * bismuth, * antisecretory drugs in the preceding 8 weeks, or * allergy to any one of the medication used in the quadruple regimens.

Keywords: helicobacter pylori second line treatment
tolerance for using virtual reality with subjects living in accommodation establishment for the elderly dependent (ehpad)

Conditions: Anxiety Disorders; Residents of Retirement Home (EHPAD)

Summary: the main purpose of this study is to assess the tolerance of the virtual environment in the elderly living in a nursing home (ehpad). it will be evaluated by the cybersickness collection after each session (1 session every other day for a total of 3 sessions).

the purpose of this muliticentric, interventional, uncontrolled study is to assess the tolerance of the virtual environment in the elderly living in a nursing home subjects who fulfil the inclusion criteria and after signing the informed consent will benefit from three individual virtual reality (vr) sessions. the sessions will be performed out with one day apart an assessment of anxiety trait and well-being of each subject will be performed before the first session (d1) and after the third (d3). an assessment of anxiety as a condition will be performed before and after each session. heart rate and blood pressure measurements will be made before, during and after each session. at the end of each session, an evaluation of cybersickness will be performed. feedback on the acceptability of the experience will be provided at the end of each session. each session will last 1 hour in total: the person will visualize a single scene of virtual reality presenting a natural environment of a duration of 7 minutes preceded by a time of introduction, evaluation and followed by a time dedicated to evaluations and maintenance.

Eligibility criteria:
inclusion criteria: * mini mental state examination (m.m.s.e) scale ≥ 20. * university of california, san diego brief assessment of capacity to consent (ubacc) scale ≥ 12/20. * living in retirment homes (ehpad). * good understanding of the french language. * benefiting from a social security scheme. * have read the newsletter and have consented to participate in the study by signing a written consent. exclusion criteria: * history of epileptic seizures. * taking antihypertensive, neuroleptic, tricyclic antidepressants or parkinsonian drugs * psychiatric disorders (schizophrenia, dissociative disorders, borderline states, paranoia). * hypertension (unless it is stabilized due to the absence of a change in antihypertensive treatment in the last 3 months and without a notable episode of orthostatic hypotension reported). * vestibular or cerebellar syndromes. * subjects under legal protection (curatorship, tutorship and safeguard of justice). * refusal to participate.

Keywords: residents of retirement home (ehpad) virtual reality anxiety disorders
vardenafil orodispersible tablet (odt) versus placebo in males with erectile dysfunction, 50% of whom are to be 65 years or older.

Conditions: Erectile Dysfunction

Summary: this study investigates the safety and efficacy of a new dosage form of vardenafil, an orodispersible tablet (odt), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. after a 4-week unmedicated phase, patients will receive vardenafil odt or matching placebo for 12 weeks. safety will be determined by laboratory and other evaluations. efficacy will be determined by the results of different questionnaires and the patient diary that will be used.


Eligibility criteria:
inclusion criteria: * males 18 years-of-age or older. * stable, heterosexual relationship for at least 6 months. * a history of erectile dysfunction (ed) for at least 6 months exclusion criteria: * any underlying cardiovascular condition, including unstable angina pectoris * history of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1 * uncontrolled atrial fibrillation / flutter at screening * history of congenital qt prolongation * history of surgical prostatectomy due to prostate cancer * hereditary degenerative retinal disorders * history of loss of vision because of naion (non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision * presence of penile anatomical abnormalities * spinal cord injury * resting or postural hypotension or hypertension * subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha-blockers, hiv (human immunodeficiency virus) protease inhibitors, itraconazole or ketoconazole, and clarithromycin and erythromycin. * subjects taking medication known to prolong qt interval, such as type ia and type 3 anti-arrhythmics. * subjects who have been confirmed with phenylketonuria (pku). * use of any treatment for ed within 7 days of visit 1.

Keywords: erectile dysfunction
the effects of oral glucose compared to sweetener drinking on hormonal/metabolic responses

Conditions: Obesity

Summary: the goal of this study is to determine the hormonal/metabolic reponse to ingestion of sugar compared to consuming artificial sweetened drink, and to evalute macronutrient consumption 24 hours post ingestion of the drinks. we hypothesize that artificially sweetened (as) consumption will lead to a relatively similar hormonal/metabolic responses as glucose consumption and therefore to secondary rise of caloric intake.

during the last two decades, the prevalence of overweight and obesity doubled. at the same time, individuals have increasingly turned to artificially sweetened (as) foods and beverages in an attempt to lose weight, or control it. several studies have found that there may be a connection between artificially sweetened food and beverages consumption and paradoxical weight gain and increased incidence of metabolic syndrome. the causal relationship between as use and weight gain haven't been proven yet. the participants will be invited to 2 meetings in which they will consume, in a randomized double blind way: 1. a beverage containing 75 gram glucose 2. a beverage containing 0.42 gram artificially sweetener (aspartame, similar sweetness level) during each meeting, the participants will drink the sweetened drink followed by blood work, as done in oral glucose challenge or tolerance test (ogtt / gtt). also, they will record their macronutrient\\caloric consumption during the 24 hour following the test.

Eligibility criteria:
inclusion criteria: * adults, healthy, men and women, ages 25-35 years, without any chronic illnesses. exclusion criteria: * family history of diabetes or overweight with bmi\> 27 * use of drugs who can influence the glucose metabolism (exp: glucocorticoids).

Keywords: obesity overweight sugar consumption metabolic syndrome artificially sweetened foods and beverages
efficacy of mhealth apps for health in a low-income, type ii diabetic, hispanic population

Conditions: Diabetes Mellitus, Type 2; Obesity

Summary: the purpose of this study is to determine the effectiveness of mobile health applications in improving health outcomes and the subsequent benefit of improving type ii diabetes outcomes in a low socioeconomic hispanic population. this study will involve a 6-month long commitment where participants will be expected to weigh themselves every morning, at the same time, and check their blood glucose readings daily before and after meals for at least three meals in the day.


Eligibility criteria:
inclusion criteria: * diagnosed with type ii diabetes * between the age of 18-64 * bmi ≥ 27 * individual annual income less than $47,520 \[covered ca income guidelines and salary restrictions\] * hispanic and/or latinx origin * monitors blood glucose regularly * owns or has access to a bathroom weight scale * owns a smartphone and willing to download mobile apps exclusion criteria: * does not check blood glucose at least once per day * on medications that promote weight gain such as antipsychotic, antidepressant, and steroid hormone medications. medications for diabetes such as insulin, thiazolidinediones or sulfonylureas are okay

Keywords: diabetes low income mhealth ehealth
tolerability and lipid lowering effect of weekly/biweekly crestor in statin intolerant patients treated with zetia

Conditions: Hypercholesterolemia

Summary: recently, research studies have shown that patients who have had trouble taking statins every day, are able to take statins if they take them only once or twice a week. the investigators are doing a research study which involves switching people who are taking ezetimibe to the statin crestor once or twice a week and to see how ell crestor lowers cholesterol and if it is tolerated.


Eligibility criteria:
inclusion criteria: * patients with a history of intolerance to statins * patients currently receiving ezetimibe * patients willing and able to provide signed informed consent exclusion criteria: * patients receiving a statin (lipitor, crestor, lescol, simvastatin, or pravachol) * stroke, tia, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within 3 months * cancer undergoing active treatment * creatinine clearance \< 40 ml/minute * active liver disease or persistent elevation of sgot or sgpt \> 2 times the upper limit of normal level * participation in any clinical study within the last 30 days * drug addition or alcohol abuse within the past 6 months * use of cyclosporine within the last 3 months * use of gemfibrozil within the last month * patients unwilling or unable to provide informed consent * patients with poor compliance * women of childbearing potential * history of rhabdomyolysis due to statins

Keywords: hypercholesterolemia
lipt - liraglutide in polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Cardiovascular Disease

Summary: polycystic ovary syndrome (pcos) affects 5-10% of women in fertile age. pcos is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. the study investigates the effect af intervention with glp-1-analog on risk markers of cardiovascular disease in women with pcos. 70 women will be included in af rct. hypothesis: glp-1-analog treatment in women with pcos (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.


Eligibility criteria:
inclusion criteria: * pcos * \>18 years * premenopausal * bmi \>25 og 25 and thereunder + insulin resistent exclusion criteria (including): * actualt or intended pregnancy * inadeqvat contraception * hormonal contraception within 6 weeks * metfoomin, glp-1-analog or dpp iv inhibitor within 3 months * medications affectiv hemostatic mechanisme * diabetes or other severe comorbidity * familar men * ...
progression of untreated pulmonary ground glass opacity

Conditions: Lung Cancer

Summary: in this study, about 2000 ggo patients will be included for a 5-year follow-up. the aim of this study is to elucidate the biological nature of pulmonary ggo lesion and provide evidence for ggo treatment.


Eligibility criteria:
inclusion criteria: * 35-80 years' old * found pulmonary ggo with chest ct scan and ct follow-up after 3 months shows that the ggo remains * diameter of ggo \> 5mm and \< 3cm * solid component of ggo in pulmonary window \< 5mm * signed informed consent form exclusion criteria: * receiving immunosuppressor or steriods * receiving chemo- or radio- therapy * can not receive regular follow-up

Keywords: ground glass opacity
anthropological survey on the use of essential oils (eos) by cystic fibrosis patients: a quantitative and qualitative approach

Conditions: Mucoviscidosis

Summary: patients and parents of patients will be asked to answer a questionnaire on paper or online, by the crcms and through communication campaigns distributed by the association vaincre la mucoviscidose (vlm). this questionnaire includes about fifty items that will take 5 to 12 minutes to complete. the study aims to interview 250 patients / parents of patients, users and non-users of essential oils. thirty patients or volunteer parents will then meet with a health anthropologist for qualitative interviews to document very precisely the modalities of use of essential oils: which ones, at what dose, advised by whom, the dedicated budget. relationships with crcm doctors, the effects felt, the side effects will also be explored. the global data of the two phases will be integrated and put into perspective with the scientific data currently available on essential oils.


Eligibility criteria:
inclusion criteria: * cystic fibrosis patient or parent of a child with cystic fibrosis exclusion criteria: * patient who refused